BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zunveyl (Benzgalantamine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zunveyl (Benzgalantamine)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07633470-668@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Zunveyl (Benzgalantamine): Phase 4 readout est. (NCT07633470)
DESCRIPTION:Zunveyl (Benzgalantamine)\, phase 4\, Alzheimer's Disease.\nStu
 dy: A Study of Zunveyl on Safety\, Tolerability\, Neuropsychiatric Symptom
 s\, and Caregiver Distress in Alzheimer's Disease (RESOLVE)\nEstimated pri
 mary completion: April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/benzgalantamine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07633470
URL:https://assetmemo.bio/drug/benzgalantamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
